Beta-2 microglobulin is a strong prognostic factor in patients with DLBCL receiving R-CHOP therapy

Kazuho Miyashita; Naoto Tomita; Masataka Taguri; Taisei Suzuki; Yasufumi Ishiyama; Yoshimi Ishii; Yuki Nakajima; Ayumi Numata; Yukako Hattori; Wataru Yamamoto; Takuya Miyazaki; Takayoshi Tachibana; Hirotaka Takasaki; Kenji Matsumoto; Chizuko Hashimoto; Sachiya Takemura; Etsuko Yamazaki; Katsumichi Fujimaki; Rika Sakai; Shigeki Motomura; Yoshiaki Ishigatsubo

doi:10.1016/j.leukres.2015.08.016

Beta-2 microglobulin is a strong prognostic factor in patients with DLBCL receiving R-CHOP therapy

Leuk Res. 2015 Aug 29:S0145-2126(15)30368-4. doi: 10.1016/j.leukres.2015.08.016. Online ahead of print.

Authors

Kazuho Miyashita¹, Naoto Tomita², Masataka Taguri³, Taisei Suzuki⁴, Yasufumi Ishiyama⁵, Yoshimi Ishii⁶, Yuki Nakajima¹, Ayumi Numata⁶, Yukako Hattori⁵, Wataru Yamamoto⁶, Takuya Miyazaki¹, Takayoshi Tachibana¹, Hirotaka Takasaki⁵, Kenji Matsumoto⁶, Chizuko Hashimoto⁷, Sachiya Takemura⁸, Etsuko Yamazaki¹, Katsumichi Fujimaki⁹, Rika Sakai⁵, Shigeki Motomura⁵, Yoshiaki Ishigatsubo¹

Affiliations

¹ Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan.
² Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan. Electronic address: cavalier@ch-yamate.dlenet.com.
³ Department of Biostatistics and Epidemiology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan.
⁴ Department of Hematology, Yokosuka City Hospital, 1-3-2 Nagasaka, Yokosuka 240-0195, Japan.
⁵ Department of Medical Oncology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, Yokohama 241-8515, Japan.
⁶ Department of Hematology, Yokohama City University Medical Center, 4-57 Urafune, Minami-ku, Yokohama 232-0024, Japan.
⁷ Department of Hematology/Oncology, Yamato Municipal Hospital, 8-3-6 Fukaminishi, Yamato 242-8602, Japan.
⁸ Department of Internal Medicine, Yokohama Ekisaikai Hospital, 1-2 Yamada-cho, Naka-ku, Yokohama 231-0036, Japan.
⁹ Department of Hematology/Immunology, Fujisawa City Hospital, 2-6-1 Fujisawa, Fujisawa 251-8550, Japan.

PMID: 26350140
DOI: 10.1016/j.leukres.2015.08.016

Abstract

Useful prognostic markers for patients with diffuse large B cell lymphoma (DLBCL) have been reported. To identify which biomarker best predicts the prognosis of patients with DLBCL, we performed a retrospective study that included 319 DLBCL patients who had received rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) therapy between 2003 and 2012. We assessed the prognostic significance of six biomarkers [lactate dehydrogenase, soluble interleukin-2 receptor, thymidine kinase activity, beta-2 microglobulin (B2M), C-reactive protein, and ferritin] and representative clinical characteristics using progression-free survival (PFS) as the endpoint. The study group included 181 men and 138 women with a median age of 63 years (range, 22-89 years). In a multivariate analysis, the serum B2M level most strongly correlated with PFS (hazard ratio, 2.11; P=0.04). In a univariate analysis, patients with serum B2M levels >1.75μg/mL (n=210) had a worse 3-year PFS rate (71.2%) than those with B2M levels <1.75μg/mL (n=109; 90.0%). Therefore, serum B2M level at the time of diagnosis is a useful prognostic indicator in DLBCL patients receiving R-CHOP.

Keywords: Beta 2-microglobulin; Diffuse large B-cell lymphoma; Non-hodgkin lymphoma; Progression-free survival; R-CHOP.